Healthcare systems have had to adapt to evolving challenges in recent years, and in response, the pharmaceutical and biotechnology sectors have implemented different innovative pricing and reimbursement models. In an article for MedTech Strategist, we explore whether similar innovative reimbursement and contracting schemes might be developed for medical technologies and how the challenges they bring might be overcome.
CRA bolsters Life Sciences Practice with appointment of Christopher Zealey as Vice President
“I am pleased to welcome Chris to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “His areas of expertise include...